The generic name of Darbital is Dupliyuzumab Injection and is indicated for the treatment of moderate-to-severe atopic dermatitis in adolescents and adults 12 years of age and older who are poorly controlled by topical medications or for whom the use of topical medications is not recommended. Dupliyu monoclonal antibody injection belongs to the whole human monoclonal antibody, selective inhibition of key signaling pathways, significantly reduce the humoral immune-type inflammatory response to increase the epidermal differentiation, barrier connection and lipid metabolism; the most common adverse reactions are injection site reactions, conjunctivitis, oral herpes, eosinophilia, headache, etc.; hypersensitivity to the product or any other excipients are prohibited. During treatment, it should be noted that if the patient develops a systemic hypersensitivity reaction, it should be discontinued immediately and appropriate treatment should be initiated; if the patient becomes infected with helminths during treatment and does not respond to anthelminthic treatment, the product should be discontinued until the infection is eliminated; if the patient develops conjunctivitis and it is not relieved by standard treatment, he or she should undergo an ophthalmologic examination; the drug should not be used concomitantly with live and live attenuated vaccines. The above is for informational purposes only. This product is generally used in hospitals by healthcare professionals.